OT Roundup: MOGENRY data, RCA report, SYD-101, OCU410

The OT Roundup returns with a callback to episode 1's biggest story, plus new data on a one-time gene therapy for geographic atrophy (GA), a fresh report on the state of retina care, and a regulatory update tied directly back to episode 1's myopia coverage.

Spotify | Apple Podcasts | Amazon Music | iHeart

Missed the last episode? Watch here!

MOGENRY holds up at 4 years

Nanoscope Therapeutics presented 4-year durability data for MOGENRY (sonpiretigene isteparvovec, formerly MCO-010), a mutation-agnostic optogenetic therapy for advanced retinitis pigmentosa (RP). Christine Kay, MD, reported that roughly 40% of treated patients maintained a 3-line visual acuity gain through year 4, while sham-arm patients remained stable or declined. "It's no longer okay to tell RP patients that there's nothing that can be done for them," Kay said.

>>> Watch the full video interview here.

RCA's first State of Retina Care report

Retina Consultants of America (RCA) released its first State of Retina Care report, surveying more than 115 affiliated specialists. Nearly 80% said RCA's operational and research support positively affected their practice, and 53% reported significantly improved patient access to clinical trials. RCA has committed nearly $40 million toward 18 new clinics since joining Cencora. The report frames those findings against a broader access gap: roughly 1 in 20 Americans live more than an hour from a retina specialist, and federal projections estimate a 28% ophthalmologist shortfall by 2038.

>>> Read the full article here.

SYD-101 and the myopia coverage gap

The FDA has scheduled an Advisory Committee meeting for October 30 to review SYD-101, a low-dose atropine formulation for pediatric progressive myopia, following a complete response letter issued in 2025. Nimesh Patel, MD, a pediatric retina specialist, discussed the access and standardization gaps left by compounded atropine, noting some formulations "don't actually contain more than 80 to 90% of the intended drug." Patel also pointed to a rise in myopia-related retinal detachments among teenagers, some of them asymptomatic.

>>> Click here to read the full article on the announcement.

>>> Click here to watch the video interview with Nimesh Patel, MD.

OCU410 shows promise in GA

Phase 2 data from the ArMaDa trial found that a single subretinal injection of medium-dose OCU410 slowed geographic atrophy (GA) progression by up to 32% compared with untreated controls, with no drug-related serious adverse events reported. Veeral Sheth, MD, called the trial's dose-response finding, where the medium dose outperformed the high dose, one of the more interesting discussion points to come out of the data. On the treatment's appeal, Sheth said, "If the value proposition to the patient is a one-time treatment ... certainly I can understand from a patient standpoint why that would be really something that they might gravitate towards."

>>> Click here to read the full article.

Where to listen

OT Roundup is part of the Eyepod podcast network.

Spotify | Apple Podcasts | Amazon Music | iHeart

New episodes of OT Roundup will be available every other Friday.